Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a potent modulator of cholesterol metabolism and plays a crucial role in the normal functioning of pancreatic islets and the progression of diabetes. Islet autocrine PCSK9 deficiency can lead to the enrichment of low-density lipoprotein (LDL) receptor (LDLR) and excessive LDL cholesterol (LDL-C) uptake, subsequently impairing the insulin secretion in β-cells. Circulatory PCSK9 levels are primarily attributed to hepatocyte secretion. Notably, anti-PCSK9 strategies proposed for individuals with hypercholesterolemia chiefly target liver-derived PCSK9; however, these anti-PCSK9 strategies have been associated with the risk of new-onset diabetes mellitus (NODM). In the current review, we highlight a new direction in PCSK9 inhibition therapy strategies: screening candidates for anti-PCSK9 from the drugs used in type 2 diabetes mellitus (T2DM) treatment. We explored the association between circulating, local pancreatic PCSK9 and T2DM, as well as the relationship between PCSK9 monoclonal antibodies and NODM. We discussed the emergence of artificial and natural drugs in recent years, exhibiting dual benefits of antidiabetic activity and PCSK9 reduction, confirming that the diverse effects of these drugs may potentially impact the progression of diabetes and associated disorders, thereby introducing novel avenues and methodologies to enhance disease prognosis.

Background Type 2 diabetes patients are particularly vulnerable to myocardial injury, including mitochondrial damage in the myocardium. This study aims to evaluate the therapeutic potential and mechanisms of dapagliflozin in mitigating myocardial mitochondrial injury under diabetic conditions. Methods A cell model was established using a high-glucose, high-fat combination. Dapagliflozin was dissolved in Dimethyl sulfoxide (DMSO) and added to the culture medium. A type 2 diabetic mouse model was induced by high-fat feeding combined with Streptozotocin (STZ) injection, with dapagliflozin administered via oral gavage. SORT1 was silenced using siRNA. Phenotypic evaluation and mechanistic analysis were performed through qPCR, Western blot (WB), activity assays, Reactive Oxygen Species (ROS) measurement, transmission electron microscopy, and Masson’s staining. Results In vitro studies, we demonstrated that under diabetic conditions, mitochondrial damage was evident, characterized by a decrease in mitochondrial respiratory chain complex content, reduced complex activity, increased ROS levels, and structural damage to mitochondria. Silencing SORT1 resulted in a similar mitochondrial phenotype under diabetic conditions, highlighting the critical role of sortilin in mitochondrial function. Addition of dapagliflozin to the culture medium significantly improved mitochondrial dysfunction caused by high glucose and high fat, a finding also confirmed in the mouse model. Moreover, dapagliflozin alleviated myocardial fibrosis induced by diabetes in the mouse model. Conclusions Our findings uncover a novel molecular mechanism through which dapagliflozin improves myocardial mitochondrial injury under diabetic conditions, suggesting SORT1 as a potential therapeutic target for treating myocardial injury in diabetes.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is primarily secreted by hepatocytes. PCSK9 is critical in liver low-density lipoprotein receptors (LDLRs) metabolism. In addition to its hepatocellular presence, PCSK9 has also been detected in cardiac, cerebral, islet, renal, adipose, and other tissues. Once perceived primarily as a “harmful factor,” PCSK9 has been a focal point for the targeted inhibition of both systemic circulation and localized tissues to treat diseases. However, PCSK9 also contributes to the maintenance of normal physiological functions in numerous extrahepatic tissues, encompassing both LDLR-dependent and -independent pathways. Consequently, PCSK9 deficiency may harm extrahepatic tissues in close association with several pathophysiological processes, such as lipid accumulation, mitochondrial impairment, insulin resistance, and abnormal neural differentiation. This review encapsulates the beneficial effects of PCSK9 on the physiological processes and potential disorders arising from PCSK9 deficiency in extrahepatic tissues. This review also provides a comprehensive analysis of the disparities between experimental and clinical research findings regarding the potential harm associated with PCSK9 deficiency. The aim is to improve the current understanding of the diverse effects of PCSK9 inhibition.

This chapter will present the reasons and difficulties for monitoring and metering on Cloud infrastructures. The approaches for monitoring of the execution environment and the network on virtualised infrastructures will be described together with the existing monitoring tools present on different commercial and research platforms.

A 37-year-old woman was admitted with a headache and sudden fainting after the onset of cervical spondylosis. The blood pressure was 75/35 mmHg, and electrocardiogram revealed sinus bradycardia with a prolonged QT/QTc interval (723/634 ms; Panel A). She was diagnosed with congenital long QT syndrome (Schwartz score: 4 points). Although hypotension was corrected, the QT/QTc interval was still prolonged (612/645 ms; Panel B). After cervical traction treatment, her symptoms were improved significantly with normalized QT/QTc interval (Panel C). There were no known pathogenic gene mutations; however, a frameshift mutation in the CACNA1S gene was identified (see Supplementary date online). During follow-up, long QT syndrome recurred and was relieved again after cervical traction. To the best of our knowledge, this is the first report of the long QT syndrome associated with cervical spondylosis. In this patient with CACNA1S gene mutation, the sympathetic nerve stimulation or excessive innervation of the cardiac autonomic nerve might play an important role, and further research is needed to investigate the relationship between CACNA1S gene and long QT syndrome.